Codexis (Nasdaq:CDXS) has announced that its board of directors has appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, to be its president and CEO.
Dilly will assume the role on August 9, 2022.
Former CEO John Nicols will retire to spend more time with his family. Nichols will continue to serve on the Codexis board until June 2023. Nichols also intends to work as a strategic advisor to the company for multiple years.
Dilly has held several senior roles in the pharmaceutical and biotech industries since the late 1980s. Firms he has worked for include SmithKline Beecham, Genentech, Chiron BioPharma and Aimmune Therapeutics.
Most recently, Dilly was the president and CEO of Sierra Oncology (Nasdaq: SRRA), which GlaxoSmithKline recently acquired for $1.9 billion.
“We are delighted that Stephen will serve as Codexis’ next CEO. He is a proven leader with a long track record of success building innovative companies,” said John Nicols, President and CEO of Codexis. “With Stephen taking over the helm, I can step back and provide the needed focus and support to my wife, who has suffered for years from a debilitating post-viral infection disorder, and dedicate more time to make a difference for her and the many others who face similar challenges through the non-profit that I chair.”
Filed Under: Drug Discovery and Development
